A cute kidney injury (AKI) is a common complication in patients with cirrhosis and is associated with significant mortality. [1] [2] [3] The most common causes of AKI in this setting are prerenal azotemia (PRA), acute tubular necrosis (ATN), and hepatorenal syndrome (HRS), and accurately determining the etiology of AKI is paramount because treatments differ considerably. [1] [2] [3] [4] [5] [6] Moreover, prognosis of patients with cirrhosis differs markedly according to the etiology of AKI. 1, 4, 7, 8 Current methods for distinguishing the cause of AKI involve urine microscopy and fractional excretion of sodium (FENa). Because these methods often are inaccurate and potentially can lead to the administration of harmful treatments and misallocation of resources, novel diagnostic methods have been sought. Urine biomarkers have been developed as potential alternatives to standard tests for the differentiation of structural (ATN) and functional (HRS and PRA) causes of AKI. 9, 10 In addition, the most intensive therapies ideally should be reserved for those at greatest risk of short-term mortality. However, because of the lack of good prognostic tools in this setting, patients often receive multiple therapies irrespective of whether they are at risk for adverse outcomes. Therefore, urine biomarkers capable of predicting short-term mortality in patients with cirrhosis and AKI may allow for more rapid and targeted treatment. 6, 11 Among the most promising urine biomarkers are interleukin (IL)18 and lipocalin 2, or neutrophil gelatinase-associated lipocalin (NGAL). IL18 and NGAL are expressed in renal tubular cells and eliminated into the urine in response to tubular injury and have been shown to be strong predictors of mortality in multiple settings. 9, 10, [12] [13] [14] Recently, several studies have examined the diagnostic and prognostic ability of IL18 and NGAL in patients with cirrhosis with AKI. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Therefore, we performed a meta-analysis to assess the ability of urine IL18 and NGAL to differentiate ATN vs functional kidney disease and to assess the ability of these biomarkers to predict all-cause mortality.
Methods

Search Strategy and Eligibility Criteria
The systematic review and meta-analysis was prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We systematically searched MEDLINE, Scopus, and ISI Web of Knowledge without date or language restrictions. The last search was conducted on December 31, 2015. We also searched conference abstracts from the American Society of Nephrology, the European Renal Association-European Dialysis and Transplant Association, the American Association for the Study of Liver Diseases, and the European Association for the Study of the Liver from January 2010 to December 2015. In addition, bibliographies of review articles and all included studies were hand-searched to identify other relevant studies. We included studies if they assessed the accuracy of 1 or more urine biomarkers in detecting ATN in patients with cirrhosis. In addition, we included studies that reported the association of 1 or more urine biomarkers with all-cause mortality in patients with cirrhosis. We only included biomarkers assessed in 3 or more independent studies. Keywords used for the search were as follows "urine biomarkers and liver cirrhosis," "NGAL and liver cirrhosis," "urine NGAL and liver cirrhosis," "neutrophil gelatinase-associated lipocalin and liver cirrhosis," "Neutrophil gelatinase-associated lipocalin," "urine NGAL," "urine IL18 and liver cirrhosis," "interleukin 18 and liver cirrhosis," and "urine IL18."
Data Extraction and Assessment of Quality
Two investigators (X.A. and J.P.) extracted the data independently. Disagreements were resolved by consensus, or, if necessary, they were resolved by referral to a third investigator. For each study, the following information was extracted: the first author's last name, year of publication, country, study design, biomarkers assessed, patient setting, hospital type, sample size, age, sex, severity of liver disease, and details of the assays and cut-off values used. For studies using biomarkers to discriminate ATN from other types of kidney impairment, the definitions of kidney impairment and ATN used, number of patients with kidney impairment, and number of patients with ATN were extracted. For studies using biomarkers to predict all-cause mortality, the duration of follow-up evaluation, number of patients followed up, and number of patients who died during the follow-up period were extracted. Each investigator also recorded the sensitivity, specificity, and area under the receiveroperating characteristic curve (AUC) for each biomarker for each outcome. We contacted the corresponding authors if further information was needed. Six authors were contacted and 5 provided the requested information. We assessed the methodologic quality of studies using the Quality Assessment of Diagnostic Accuracy Studies 2 tool (Supplementary Table 1 ). 26 
Statistical Analysis
We performed meta-analyses for sensitivity and specificity using a bivariate logistic mixed-effects model. We calculated the number of true positives, true negatives, false positives, and false negatives for each study, and from these we estimated the pooled sensitivity and specificity with its 95% confidence interval (CI). We assumed random effects with a bivariate normal distribution.
In addition, we performed meta-analyses for the AUC for each outcome. If the study reported the AUC and 95% CI instead of the standard error, we imputed the standard error by dividing the difference between the upper and lower CI by 3.92. 27 We pooled the individual study estimates under the random-effects model and expressed the overall estimate as a pooled AUC with its 95% CI. When evaluating the pooled study estimates, we considered poor accuracy as less than 0.7, moderate accuracy as 0.7 to 0.8, excellent as 0.8 to 0.9, and outstanding accuracy as greater than 0.9. 28 We calculated the I 2 statistic to assess heterogeneity across studies. When evaluating heterogeneity, we considered no heterogeneity as less than 25%, low heterogeneity as 25% to 50%, moderate heterogeneity as 50% to 75%, and high heterogeneity as greater than 75%. 29 Publication bias was assessed visually by inspecting funnel plots and statistically by using the Egger et al 30 
Results
Study Identification and Selection
The study selection process is shown in Figure 1 . Our database search identified 264 citations, from which 54 were selected for full-text evaluation. From these, we identified 8 articles eligible to be included in the metaanalysis.
Study Characteristics and Data Collection
The characteristics of the 8 studies included in the meta-analysis are reported in Table 1 . These prospective studies encompassed 1129 patients with cirrhosis enrolled from university-affiliated tertiary care centers. The sample sizes of individual studies ranged from 55 to 241, the mean age ranged from 53 to 63 years, the proportion of male patients ranged from 62% to 79%, and the mean model for end-stage liver disease score ranged from 15 to 28. Most studies were performed in hospitalized patients with cirrhosis, and most were conducted in Europe or Asia. In each of the studies, urine samples were collected shortly after enrollment. In addition, urine IL18 and NGAL measurements were obtained using researchbased assays, with the exception of the ARCHITECT platform (Abbott, Abbott Park, IL) used in the study by Treeprasertsuk et al, 25 which is a standardized clinical platform for urine NGAL measurement.
Study Quality and Publication Bias
Study quality is reported in Supplementary Table 1 . All studies used a prospective study design and avoided inappropriate exclusions. Five studies enrolled patients consecutively, and the other studies did not specify the manner of enrollment. Applicability concerns existed for 3 studies that enrolled patients in the intensive care unit or that enrolled patients with bacterial infection or acute decompensation of cirrhosis. No studies used a prespecified cut-off value, but rather determined optimal cut-off values using receiver operating characteristic curve analysis. All studies used an immunoassay to measure biomarker levels.
Funnel plots were generated to assess publication bias (Supplementary Figure 1) . The funnel plots were not markedly asymmetric. In addition, publication bias was not detected using the Egger et al 30 regression model (urine IL18 for the diagnosis of ATN, P ¼ .32; urine NGAL for the diagnosis of ATN, P ¼ .32; urine IL18 for predicting all-cause mortality, P ¼ .35; and urine NGAL for predicting all-cause mortality, P ¼ .51).
Urine Interleukin 18 and Neutrophil GelatinaseAssociated Lipocalin for Diagnosis of Acute Tubular Necrosis
Six studies used urine biomarkers to differentiate ATN from other types of kidney impairment in patients with cirrhosis. Of these, 4 studies used urine IL18 and 5 studies used urine NGAL (Supplementary Table 2 ). The prevalence of ATN varied from 26% to 35%. Three studies used the Acute Kidney Injury Network criteria for kidney impairment, 2 studies used serum creatinine with a higher threshold than the Acute Kidney Injury Network criteria, and 1 study used a combined HRS/ATN definition. The definitions of kidney impairment and ATN used are shown in Supplementary Table 3 .
The pooled sensitivity for the diagnosis of ATN for urine IL18 was 0.80 (95% CI, 0.59-0.92) and the pooled specificity was 0.88 (95% CI, 0.82-0.93) Figure 1 . Flow diagram of study selection. (Figure 2A ). The area under the receiver operating characteristic curve was 0.88 (95% CI, 0.79-0.97) ( Figure 3A) . The pooled sensitivity for urine NGAL was 0.86 (95% CI, 0.68-0.94) and the pooled specificity was 0.82 (95% CI, 0.75-0.87) ( Figure 2B ). The area under the receiver operating characteristic curve was 0.89 (95% CI, 0.84-0.94) ( Figure 3B ). There was high heterogeneity between studies (I 2 ¼ 90%; P < .01) for urine IL18, and moderate heterogeneity between studies (I 2 ¼ 61%; P ¼ .04) for urine NGAL. Each study identified optimal cut-off values for urine IL18 and NGAL concentration. The reported cut-off values for IL18 and NGAL to diagnose ATN varied considerably from 54 to 1109 pg/mL and 137 to 365 ng/mL, respectively.
Urine Interleukin 18 and Neutrophil GelatinaseAssociated Lipocalin for Prediction of Mortality
Three studies assessed the accuracy of urine IL18 and 5 studies assessed the accuracy of urine NGAL for predicting all-cause mortality (Supplementary Table 4 ). One study followed up patients during hospitalization, and the other 5 studies followed up patients from 1 to 6 months after discharge. The number of patients followed up ranged from 51 to 168. The overall mortality during the follow-up period ranged from 14% to 65%.
The pooled sensitivity for urine IL18 was 0.69 (95% CI, 0.56-0.79) and the pooled specificity was 0.75 (95% CI, 0.68-0.81) ( Figure 4A ). The area under the receiver Figure 2 . Sensitivity and specificity of (A) urine IL18 and (B) urine NGAL for the diagnosis of ATN.
operating characteristic curve was 0.76 (95% CI, 0.68-0.85) ( Figure 5A ). The pooled sensitivity for urine NGAL was 0.60 (95% CI, 0.39-0.78) and the pooled specificity was 0.83 (95% CI, 0.69-0.92) ( Figure 4B ). The area under the receiver operating characteristic curve was 0.76 (95% CI, 0.71-0.82) ( Figure 5B ). There was moderate heterogeneity between studies for both urine IL18 (I 2 ¼ 68%; P ¼ .04) and urine NGAL (I 2 ¼ 51%; P ¼ .08). The prognostic cut-off values for urine IL18 and NGAL concentration varied considerably from 53 to 299 pg/mL and 72 to 287 ng/mL, respectively.
Discussion
One of the main challenges for physicians caring for patients hospitalized with complications of cirrhosis is unraveling the cause of severe AKI, particularly differentiating between HRS and ATN. 31, 32 Serum creatinine is not helpful in this regard, and renal biopsies usually are not performed because of the high risk caused by marked coagulation abnormalities in patients with advanced cirrhosis. The inability to make a distinction between HRS and ATN is critical because treatments differ considerably. HRS may be reversed with restoration of renal perfusion, through vasoconstrictor therapy plus intravenous albumin, whereas patients with ATN may be treated with dialysis or combined liver-kidney transplantation. Furthermore, the most aggressive therapies, such as transplantation, should be reserved for patients with the highest risk for progressive renal dysfunction and death.
In the past few years, there has been increasing interest in assessing the potential usefulness of renal biomarkers in this setting and a number of studies have been published with this objective. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] The rationale for using biomarkers in the differential diagnosis between ATN and functional kidney impairment, particularly HRS, is straightforward. Biomarkers of kidney injury should be increased in the urine of patients with ATN, but not in patients with HRS, a condition of functional kidney impairment caused by arterial vasoconstriction, which lacks structural injury to kidney tubular cells. 11, 32, 33 The current meta-analysis assesses the performance of 2 kidney injury biomarkers, IL18 and NGAL, for the diagnosis and prognosis of AKI in patients with cirrhosis. IL18 is a mediator of inflammation and ischemic injury in many organs. In the kidney, tubular cells and interstitial macrophages produce IL18 in response to injury. 34, 35 Human studies have indicated that IL18 is a biomarker of tubular damage because urinary levels of IL18 are increased markedly in patients with ATN, whereas they are low in patients with AKI because of volume depletion and in patients without AKI. A number of prospective studies and meta-analyses have shown that urinary IL18 can predict the clinical onset of AKI moderately well across a wide range of clinical settings, including critically ill patients, patients undergoing cardiac surgery, and patients receiving kidney transplantation. 36, 37 Moreover, urinary IL18 also has been shown to have a relatively good ability to predict the need for renal replacement therapy and mortality during hospitalization. 9, 13, 36, 37 NGAL is a 25-kilodalton protein that derives from the lipocalin-2 gene. 38 Under normal conditions, NGAL is very abundant in the cytosolic granules of neutrophils but barely expressed in other cells. However, as a result of tissue injury, NGAL is overexpressed in a variety of human tissues, including the kidneys, liver, and lungs. [38] [39] [40] [41] In patients with kidney injury, NGAL is detected in the urine before an increase in serum creatinine. Moreover, urine levels are increased markedly in AKI because of ATN, but only minimally increased in AKI as a result of prerenal failure. 12 In AKI caused by ATN, urine NGAL appears to derive mainly from increased expression in epithelial cells of the distal nephron. However, it also may derive from filtration and decreased reabsorption owing to proximal tubular injury. 42 A number of large prospective studies and meta-analyses have shown that urine NGAL is a good diagnostic biomarker of AKI, specifically ATN. Several meta-analyses also have shown the accuracy of NGAL for predicting the clinical onset of AKI in a number of patient settings, such as the intensive care unit, cardiopulmonary bypass surgery, and kidney transplantation, as well as for predicting renal replacement therapy and mortality. 43, 44 Although several meta-analyses evaluated NGAL and IL18 in various clinical settings, none of these metaanalyses investigated the diagnostic and prognostic performance of IL18 and NGAL in patients with cirrhosis and AKI. This topic is of clinical relevance because, as mentioned previously, patients with cirrhosis frequently develop HRS, a severe functional form of AKI, not seen in patients without liver disease. 11, 32 Making the distinction between HRS and ATN is very relevant for therapeutic purposes, particularly in candidates for liver transplantation. 5, 6, 11, 31 The results of the current meta-analysis show that both urinary NGAL and IL18 have good sensitivity and specificity for identifying ATN in patients with cirrhosis and therefore differentiating ATN from HRS (IL18, 0.80 and 0.88; NGAL, 0.86 and 0.82, respectively). These values are similar or even better than those reported in different patient settings. 13, 36, 37 Moreover, the AUC for the diagnosis of ATN was 0.88 and 0.89 for IL18 and NGAL, respectively; these values are higher than those found in most studies in different patient settings. 37, 43 As expected, values of biomarkers were lower in patients with HRS and higher in patients with ATN. Considering that both IL18 and NGAL are inflammatory mediators, it is worth mentioning that the origin of IL18 and NGAL found in the urine of patients with cirrhosis may not be related exclusively to kidney injury but also to the intensive systemic inflammation that is characteristic of patients with cirrhosis. 45 Moreover, in addition to their ability to detect ATN, urine IL18 and NGAL predicted short-term mortality after AKI moderately well (IL18: AUC, 0.76; NGAL: AUC, 0.76). Furthermore, the assays used to measure both urine IL18 (Bio-Rad, Hercules, CA; MBL, Nagoya, Japan) and NGAL (Bio-Rad, Hercules, CA; BioPorto, Gentofte, Denmark; Bio-Vendor, Heidelberg, Germany; Abbott, Abbott Park, IL) are commercially available worldwide.
This meta-analysis had some limitations that should be acknowledged. First, there were differences in study characteristics (eg, age, sex, model for end-stage liver disease score, sample collection time, biomarker assay), which may have contributed to the heterogeneity observed in the results. 46 However, the number of available studies limited our ability to investigate potential sources of heterogeneity through subgroup analyses and meta-regression. Second, the criteria used to define ATN were slightly different across studies, and, as expected, kidney biopsies were not performed in any study to confirm ATN. Third, the duration of follow-up evaluation was different among studies so mortality at a specific time point could not be assessed. Fourth, we could not determine the ideal diagnostic and prognostic cut-off values for IL18 and NGAL because we did not have the raw data to perform receiver operating characteristic curve analysis. Finally, although these biomarkers are able to differentiate between structural (ATN) and functional (PRA and HRS) causes of kidney impairment, they are unable to differentiate between PRA and HRS. However, other biomarkers such as FENa have been shown to distinguish HRS from PRA and ATN. 21 Therefore, urine IL18 and NGAL used in conjunction with FENa may be able to make the clinically important distinction between ATN, HRS, and PRA. Despite these limitations, our meta-analysis provides a comprehensive assessment and robust evidence of the accuracy of urine biomarkers for assessing AKI and prognosis in patients with cirrhosis.
In summary, this meta-analysis suggests that both urinary IL18 and NGAL are of value for distinguishing between AKI owing to ATN and HRS. Moreover, both biomarkers show predictive value for all-cause mortality in patients with cirrhosis. These findings indicate that incorporating urine IL18 and NGAL into clinical decision making has the potential to guide treatment more accurately. Furthermore, these biomarkers also potentially can be used to enrich clinical trials of AKI. For example, in a HRS trial, urine IL18 and NGAL could be used as diagnostic biomarkers to preferentially enroll individuals with HRS and reduce misclassification with ATN. In addition, they could be used as prognostic biomarkers to identify patients likely to reach trial end points (such as all-cause mortality). Further studies with standardized diagnostic criteria are needed for Food and Drug Administration and European Medicines Agency qualification of these biomarkers for drug development and to identify relevant cut-off values for clinical application. 
